Interferon response in chronic myeloid leukaemia correlates with ABL/BCR expression: a preliminary study

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Alpha-Interferon (IFN) is a treatment for chronic myeloid leukemia (CML), but predicting patient response remains challenging.
• The role of BCR/ABL fusion gene in CML is established, yet the prognostic significance of BCR breakpoint sites and resulting mRNA types is debated.
• The clinical relevance of the newly identified ABL/BCR mRNA in CML prognosis and therapy response is largely unexplored.

Purpose of the Study:

• To investigate the potential correlation between BCR/ABL, ABL/BCR, ABL, and BCR gene expression and clinical outcomes in CML patients treated with IFN.
• To determine if the ABL/BCR mRNA transcript can serve as a predictive marker for IFN response in CML.

Main Methods:

• Utilized a two-step reverse transcriptase polymerase chain reaction (RT-PCR) technique.
• Detected and quantified BCR/ABL, ABL/BCR, ABL, and BCR mRNA transcripts in 24 CML patients at the time of IFN treatment initiation.
• Correlated transcript expression levels with patient prognosis, clinical progression, and response to IFN therapy.

Main Results:

• No significant correlation was observed between the expression of BCR, ABL, or BCR/ABL mRNA and CML prognosis or IFN treatment response.
• A notable association was found between the presence of ABL/BCR mRNA and achieving a major cytogenetic response to IFN therapy (7/10 positive patients vs. 2/13 negative patients, P = 0.013).

Conclusions:

• The expression of BCR, ABL, or BCR/ABL mRNA does not appear to predict prognosis or IFN response in CML patients.
• The ABL/BCR mRNA transcript shows promise as a potential predictive biomarker for major cytogenetic response to alpha-Interferon in chronic myeloid leukemia.
• Further research is warranted to validate these findings and elucidate the role of ABL/BCR mRNA in CML pathogenesis and treatment response.